The perspectives of the application of phage therapy in chronic bacterial prostatitis
- PMID: 20698884
- DOI: 10.1111/j.1574-695X.2010.00723.x
The perspectives of the application of phage therapy in chronic bacterial prostatitis
Abstract
Chronic bacterial prostatitis (CBP) is a long-lasting and crippling disease that strongly impacts the patient's quality of life. The diagnosis of CBP is difficult and the treatment regimens are not always successful. Poor penetration of antibiotics to the prostate tissue, the drug resistance of uropathogens, the adverse events associated with antibiotic treatment, the persistence of prostatic calculi, and biofilm formation in the prostate gland are factors that contribute toward decreasing the cure rate of CBP. The phenomenon of increasing antibiotic resistance, which has also been called a clinical super-challenge, has revived interest in therapy using bacterial viruses (bacteriophages or phages). Because of their mechanism of action, which is completely different from those of all antibiotics, phages are effective even against multidrug-resistant bacteria. Here, we describe the current perspectives on the possible application of phage therapy (PT) in treating CBP. The advantages of therapeutic phages, including their interactions with bacterial biofilm, as well as the safety of PT are discussed.
© 2010 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.
Similar articles
-
The role of antibiotics in chronic bacterial prostatitis.Int J Antimicrob Agents. 2005 Jul;26(1):1-7. doi: 10.1016/j.ijantimicag.2005.04.013. Int J Antimicrob Agents. 2005. PMID: 15970433 Review.
-
Treatment of chronic bacterial prostatitis.Clin Pharm. 1984 Jan-Feb;3(1):49-55. Clin Pharm. 1984. PMID: 6365416 Review.
-
Synergistic effect between catechin and ciprofloxacin on chronic bacterial prostatitis rat model.Int J Urol. 2005 Apr;12(4):383-9. doi: 10.1111/j.1442-2042.2005.01052.x. Int J Urol. 2005. PMID: 15948727
-
Biofilms in chronic bacterial prostatitis (NIH-II) and in prostatic calcifications.FEMS Immunol Med Microbiol. 2010 Aug;59(3):337-44. doi: 10.1111/j.1574-695X.2010.00659.x. Epub 2010 Feb 17. FEMS Immunol Med Microbiol. 2010. PMID: 20298500
-
[Etiotropic therapy of chronic bacterial prostatitis].Urologiia. 2008 May-Jun;(3):36, 38-41. Urologiia. 2008. PMID: 18669346 Russian.
Cited by
-
A Novel Phage Cocktail Therapy of the Urinary Tract Infection in a Mouse Model.Arch Razi Inst. 2021 Nov 30;76(5):1229-1236. doi: 10.22092/ari.2021.356004.1762. eCollection 2021 Nov. Arch Razi Inst. 2021. PMID: 35355758 Free PMC article.
-
Phage Prevalence in the Human Urinary Tract-Current Knowledge and Therapeutic Implications.Microorganisms. 2020 Nov 17;8(11):1802. doi: 10.3390/microorganisms8111802. Microorganisms. 2020. PMID: 33212807 Free PMC article. Review.
-
Male accessory gland infection (MAGI): Over-diagnosed or under treated in infertile men?Arab J Urol. 2024 Dec 28;23(3):201-209. doi: 10.1080/20905998.2024.2445332. eCollection 2025. Arab J Urol. 2024. PMID: 40747479 Free PMC article. Review.
-
Phage Therapy in the 21st Century: Is There Modern, Clinical Evidence of Phage-Mediated Efficacy?Pharmaceuticals (Basel). 2021 Nov 13;14(11):1157. doi: 10.3390/ph14111157. Pharmaceuticals (Basel). 2021. PMID: 34832939 Free PMC article.
-
Successful use of a phage endolysin for treatment of chronic pelvic pain syndrome/chronic bacterial prostatitis.Front Med (Lausanne). 2023 Aug 15;10:1238147. doi: 10.3389/fmed.2023.1238147. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37649979 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical